NRx Pharmaceuticals (NASDAQ: NRXP) filed a New Drug Application for its intravenous ketamine treatment for suicidal depression as it tries to expand its psychiatric clinic network, the company said Monday.
The company, which focuses on treatments for central nervous system disorders including suicidal depression and post-traumatic stress disorder, also released its…
Please login to read all 638 words.
